Tg Therapeutics (TGTX) Interest Expenses (2011 - 2026)

Tg Therapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 13.45% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $27.7 million, a 37.21% increase from a year earlier, with the FY2025 full-year figure at $96.7 million, down 6.77% from the prior year.
• Interest Expenses grew to $7.7 million in Q1 2026 per TGTX's latest filing, from $6.5 million in the prior quarter.
• Across five years, Interest Expenses topped out at $17.3 million in Q2 2022 and bottomed at -$1.4 million in Q4 2023.
• The 5-year median for Interest Expenses is $6.8 million (2025), against an average of $8.3 million.
• Across the five-year window, Interest Expenses slumped 122.49% in 2023 and soared 947.84% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $6.3 million in 2022, then slumped by 122.49% to -$1.4 million in 2023, then surged by 947.84% to $12.0 million in 2024, then plunged by 45.47% to $6.5 million in 2025, then climbed by 17.34% to $7.7 million in 2026.
• Per Business Quant, the three latest TGTX Interest Expenses figures stand at $7.7 million (Q1 2026), $6.5 million (Q4 2025), and $11.1 million (Q3 2025).